Suppr超能文献

检测加拿大三个地区不受监管的毒品供应中的合成大麻素掺假情况。

Detection of synthetic cannabinoid adulteration in the unregulated drug supply in three Canadian settings.

机构信息

British Columbia Centre on Substance Use, Vancouver, Canada.

Department of Medicine, University of British Columbia, Vancouver, Canada.

出版信息

Drug Alcohol Rev. 2021 May;40(4):580-585. doi: 10.1111/dar.13237. Epub 2020 Dec 22.

Abstract

INTRODUCTION

Novel psychoactive substances (NPS) are increasingly being consumed worldwide, with synthetic cannabinoids and synthetic opioids being the second and third most commonly used NPS, respectively. Certain synthetic cannabinoids can produce significant harms, particularly when used with opioids. The objective of this study was to characterise the presence of synthetic cannabinoids in the unregulated drug supply in three Canadian settings METHODS: In the British Columbia setting, all samples were first analysed at point-of-care using combination Fourier-transform infrared (FTIR) spectroscopy and fentanyl immunoassay strips prior to confirmatory testing using quantitative nuclear magnetic resonance spectroscopy, gas chromatography/mass spectrometry (GC/MS) and/or liquid chromatography/mass spectrometry (LC/MS). In the Toronto, Ontario setting, the samples were analysed directly by GC/MS, LC/MS liquid chromatography-high resolution/mass spectrometry.

RESULTS

Between January 2018 and December 2019, 38 (2.8%) synthetic cannabinoid samples were detected in the unregulated drug supply (25/909 in British Columbia and 13/440 in Ontario). In British Columbia and Ontario, 76% and 85% of samples, respectively, were expected by individuals to be an opioid. Synthetic cannabinoids detected included AMB-FUBINACA, AB-FUBINACA, 5-fluoro-MDMB-PINACA, and 5-fluoro-MDMB-PICA, and largely co-occurred with fentanyl. In the British Columbia context, Fourier-transform infrared spectroscopy failed to detect synthetic cannabinoid compounds in almost half (48%) of the samples at point-of-care.

DISCUSSION AND CONCLUSIONS

As point-of-care technologies failed to detect these compounds in many occasions, our findings demonstrate the importance of laboratory confirmatory analysis to identify NPS. Given the high risk of harm associated with the consumption of synthetic cannabinoids, further research should investigate the reasons for adulteration.

摘要

简介

新型精神活性物质(NPS)在全球范围内的使用越来越多,合成大麻素和合成阿片类药物分别是第二和第三大常用 NPS。某些合成大麻素会产生重大危害,特别是与阿片类药物一起使用时。本研究的目的是描述在加拿大三个地区的无监管药物供应中合成大麻素的存在情况。

方法

在不列颠哥伦比亚省,所有样本均首先使用组合傅里叶变换红外(FTIR)光谱和芬太尼免疫测定条在现场进行分析,然后使用定量核磁共振光谱、气相色谱/质谱(GC/MS)和/或液相色谱/质谱(LC/MS)进行确证测试。在安大略省多伦多市,样本直接通过 GC/MS、LC/MS 液相色谱-高分辨率/质谱进行分析。

结果

2018 年 1 月至 2019 年 12 月,在无监管药物供应中检测到 38 种(2.8%)合成大麻素样本(不列颠哥伦比亚省 25/909,安大略省 13/440)。在不列颠哥伦比亚省和安大略省,分别有 76%和 85%的样本被个人预期为阿片类药物。检测到的合成大麻素包括 AMB-FUBINACA、AB-FUBINACA、5-氟-MDMB-PINACA 和 5-氟-MDMB-PICA,并且主要与芬太尼共同出现。在不列颠哥伦比亚省的情况下,现场检测技术几乎有一半(48%)的样本无法检测到合成大麻素化合物。

讨论和结论

由于现场检测技术在许多情况下未能检测到这些化合物,因此我们的研究结果表明,实验室确证分析对于识别 NPS 非常重要。鉴于与使用合成大麻素相关的高风险危害,应进一步研究导致掺假的原因。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验